How would you treat a patient with symptomatic and rapidly progressing metastatic HR+, HER2 low breast cancer with PIK3CA WT, ESR1 mutated, TMB high after progression on CDK 4/6 inhibitor, a taxane, and T-DXd?
Answer from: Medical Oncologist at Academic Institution
With disease progressing on increasing number of systemic therapy lines, the likelihood of having a response diminishes. In the absence of an impending organ crisis, one could consider fulvestrant with alpelisib, elacestrant, or pembrolizumab. However, if the patient is facing an impending organ fai...
Comments
Medical Oncologist at NYU Winthrop Hospital Can use capivasertib with fulvestrant - CAPItello-...
Medical Oncologist at Loyola University Chicago Stritch School of Medicine @Mohammed F. Ali and @Robert Wesolowski have you m...
Medical Oncologist at University of Wisconsin Hospital & Clinics @Elizabeth Henry,
I haven't but, capivasertib is ...
Can use capivasertib with fulvestrant - CAPItello-...
@Mohammed F. Ali and @Robert Wesolowski have you m...
@Elizabeth Henry, I haven't but, capivasertib is ...